Business Context and Reporting Period
This Form 8-K filing by AnaptysBio, Inc. (ANAB) covers the date of November 20, 2025. The report details significant legal developments regarding the company's Collaboration and Exclusive License Agreement with TESARO, Inc. (a subsidiary of GlaxoSmithKline or "GSK").
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It notes that milestone and royalty payment obligations to AnaptysBio under the Collaboration Agreement continue to be due during the ongoing legal proceedings.
Material Changes and Events
- Litigation Initiated: On November 20, 2025, AnaptysBio filed a Verified Complaint in Delaware Chancery Court against TESARO, Inc. and GSK.
- Alleged Breaches: AnaptysBio alleges TESARO materially breached the Collaboration Agreement by:
- Violating exclusivity obligations by participating in clinical trials with competing PD-1 antagonists (e.g., Keytruda) alongside Jemperli.
- Failing to use "Commercially Reasonable Efforts" to maximize commercial returns for Jemperli, allegedly favoring GSK's antibody-drug conjugate (ADC) candidates.
- Counter-Suit: On the same day, TESARO filed a lawsuit against AnaptysBio, seeking injunctive relief and claiming AnaptysBio breached the agreement by improperly alleging a breach. AnaptysBio contends these claims are meritless and violate Delaware's anti-SLAPP statute.
- Historical Context: A similar dispute in 2020 regarding GSK's Zejula program was settled, resulting in cash payments and increased royalties for AnaptysBio.
Outlook, Risks, and Management Commentary
Management intends to pursue all appropriate legal remedies, including seeking dismissal of TESARO's claims. The parties have agreed to an expedited schedule with the Delaware Chancery Court, with a trial anticipated in July 2026. The filing includes forward-looking statements regarding the potential termination of the Collaboration Agreement, the return of Jemperli rights to AnaptysBio, and the nature of potential remedies, all of which are subject to significant risks and uncertainties.
Investor Verification Checklist
- Verify the specific terms of the Collaboration Agreement regarding exclusivity and "Commercially Reasonable Efforts."
- Monitor the status of the expedited trial schedule set for July 2026.
- Assess the potential impact of the litigation on future royalty and milestone payments from TESARO/GSK.
- Review the details of TESARO's counter-claims and the company's defense strategy under Delaware's anti-SLAPP statute.
- Check for any updates on the commercial performance of Jemperli and competing PD-1 antagonist trials.